Duchenne muscular dystrophy (Duchenne)

“We are proud to serve the UK rare diseases community and play our part in the mission to improve the lives of patients with Duchenne muscular dystrophy”

TJ Bailey-Burnley, General Manager, UK and Ireland

What is Duchenne?

Duchenne is a rare neuromuscular disorder, characterised by progressive muscle damage and weakness. It occurs almost exclusively in males due to its X-linked recessive genetic pattern 1. In the UK, about 100 boys are born with Duchenne each year, and it affects an estimated 2,500 people in the UK at any one time 2. Girls are not typically affected, but they can be carriers of the genetic mutation and can have what is known as a dystrophinopathy.1

Duchenne is caused by mutations in the dystrophin gene resulting in an absence or non-functional dystrophin, a key structural protein protecting the muscle cells from repeated contraction-induced damage.1

How does Duchenne affect the body?

For individuals with Duchenne, their muscles are under constant siege, vulnerable to damage from everyday activities. A normal healthy muscle can counteract muscle damage thanks to its inner capability to regenerate new muscle cells. However, the muscles of people affected by Duchenne are more susceptible to injury and their muscle regeneration is impaired. The body naturally tries to repair the damage, but continuous muscle fibre damage leads to chronic inflammation, and the muscle fibres are replaced by scarring (fibrous tissue) and fat deposits. Over time, the muscles lose their capability to regenerate and their ability to contract, resulting in loss of muscle mass and weakness. It can be a relentless battle that families and doctors face together. 3

Duchenne Community

The community is united in enhancing the quality of life for families affected by Duchenne, with a focus on the needs of today and tomorrow. We aim to deliver exceptional research and support, helping families along their Duchenne journey. In doing so, we focus our efforts on prioritising and fulfilling the most critical needs that remain unaddressed.

Addressing unmet needs - Duchenne Muscular Dystrophy DMD - Rare Disease - Italfarmaco SpA

Addressing unmet needs

The treatment landscape is evolving, with research focusing on a variety of approaches, and major advances that are leading towards solutions that may change the course of the disease for patients living with Duchenne.

Support and collaboration - Duchenne Muscular Dystrophy DMD - Rare Disease - Italfarmaco SpA

Support and collaboration

What makes the Duchenne community so extraordinary? It’s the unwavering desire to partner, share, and collaborate. This global perspective weaves together the shared experiences of those living with Duchenne, emphasising the commonalities in challenges, hopes, and the relentless pursuit of a better future for all affected by this condition.

GB-ITF-26-00003 Date of preparation: October 2026
  1. Venugopal V, Pavlakis S. Duchenne muscular dystrophy. Last updated 10 July 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482346
  2. National Institute for Health and Care Excellence (NICE), Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 draft scope: https://www.nice.org.uk/guidance/awaiting-development/gid-ta11437/documents. Accessed August 2026.
  3. Aartsma-Rus A. Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy. Front Cell Dev Biol. 2025;12:1514898.